The role of AI in drug discovery and delivery stands at a pivotal juncture. The integration of advanced computational approaches is not just an emerging trend but a fundamental shift in how we approach the creation of new therapeutics.

My guest for this week’s episode is Chris, Co-Founder & Product Lead at Nanograb, a YC biotech company (YC S23) that uses AI to generate the best combination of binders to treat different diseases.

Prior to co-founding Nanograb, Chris had a career in HSBC Hong Kong. Chris has a master degree in Biomaterials and Tissue Engineering at Imperial College London. His experience across biotech, finance and entrepreneurship give his unique insights you won’t want to miss.

-

Join us this episode to hear about:

00:59 Chris’ early upbringing and connection with his entrepreneurial drive
07:38 Chris’ gravitation from finance toward entrepreneurship
17:53 The founding team
26:08 About Nanograb
31:31 Chris’ YC experience
38:12 Chris’ view on hiring
42:04 Advice to 20-year old self

-

☕️ References:

Y Combinator: a startup accelerator that invests in a wide range of startups.
AlphaFold: an artificial intelligence program developed by DeepMind, a subsidiary of Alphabet, which performs predictions of protein structure. Having revealed millions of intricate 3D protein structures, it is helping scientists understand how all of life's molecules interact.

-

☕️ About Us:

Victoria: Management Consultant | VC | Entrepreneur | Imperial College London Chemistry alum | 🔗 LinkedIn
Jecci: Documentary Filmmaker | Cambridge MPhil Social Anthropology alum | 🔗 LinkedIn

-

☕️ Production Team:

Host: Victoria

Audio Editing: Jeff

-

☕️ Disclaimer:

Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any fund.

10 YC Founder: Forging AI for next-generation targeted drugs

AirCafe